On the basis of suggestedc linical efficacy in an uncontrolled study in ninety-sevenp atientsw ith unstable angina,ana nimal study was conducted to investigate antithromboticsynergybetween orallya dministered heparin and arginine.A rat venous thrombosis modeltestedthe difference in thrombus formation when heparin (7.5 mg/kg)and arginine (113 mg/kg)wereadministered,alone or in combination, by stomacht ube witham inimumo f2 0r ats/group.Oral heparin, arginine,and heparin plus arginine reducedthrombus formation by 50%,75%,and 90%,respectively, whencompared to salineadministration.Heparin was recoveredfromendothelium,yet there was little or no observKeywords Heparin,thrombosis,endothelium,arginine,oral able plasma anticoagulant activity.Ano rally administeredl owmolecular-weight anticoagulant glycosaminoglycan mixture, sulodexide(7.5 mg/kg), showed an 88%reductioninstable thrombusformation when administeredalone but showed no synergy with oral arginine.A 28-daystudy with oral sulodexide (2.9mg/ kg)and arginine (43.9 mg/kg), 20 rats/group, showed antithrombotic activity withminimalanticoagulant activity indicating suitability forl ong term treatment. Thesef indingss uggestt he endotheliallocalization of heparin and asynergistic antithrombotic effect fororally administeredheparin and arginine.
Introduction
Previous investigations have demonstrated that heparin has antithromboticactivity when administered orally in rat thrombosis models (1, 2) . Several studiessuggest that heparins arefound on the endothelial surfacew ithin minutesf ollowing orala dministration with minimal observedevidenceofplasma distribution. Endothelial concentrations of heparin arer eported to be 1,000 -10,000timesthe levels measurable in plasma followingoral administration to rats (3, 4) . If similareffectsoccur on humanendothelium following oralh eparin administration, potent antithrombotic effectswould be anticipated without systemic anticoagulation.
Arginine and heparans ulfate have important roles in the functional and molecular organization of vascularhomeostasis and hemostasis. Arginine is the substrate for eNOS in the endothelial production of NO (5) .NOreduces endothelialadhesiveness, preventsplateletaggregation, and results in vasorelaxation (6) (7) (8) . Arginine is also reported to have anticoagulant properties (9) . Arginine groups on peptides aremajor determinants in their interaction with endogenous heparan sulfates on the endothelials urfaceo fb lood vessels (10) .W hile arginine only weaklyi nteracts with the O -sulfoesters of heparan sulfatea nd heparin, this binding is stronger than that of other basic amino acids (11) .F urthermore,h eparin induces eNOS activity (12) , and heparin as well as NO increase the biosynthesis of endothelialh eparan sulfatew ith increased amounts of AT III binding sites ( 13, 14) . Evidencea lso suggests both NO and heparan sulfated eficienciesm ay causee ndothelial dysfunction, prothromboticeffects, and plaqueformation (15-21).Thus, an important relationship exists betweenheparin,heparan sulfate,arginineand NO in promoting antithrombotic activityand vascular health. Basedonthese reports, we speculated that administration of both heparinand arginine togetherw ould simultaneouslyincreaseendothelial heparansulfate andNOand possiblye xhibit antithrombotic synergy. Since orala dministration of heparini n rats results in its enhanced deposition on the endothelium relative to plasma levels (3), we chosethis routefor our investigation.
We report herebeneficialcardiovasculareffectsinaseriesof patients, with unstable angina in aclinical setting, treated for12 monthswith oral heparinplus arginine. Dataare alsopresented confirming synergy of oral heparinp lus arginine in inhibiting thrombus formation in an establishedr at venous thrombosis model of 4-hour duration. Oral sulodexide, aglycosaminoglycan mixture (22) , had antithromboticactivity in a4-hour and 28-day study when combined with arginine.
Materials andmethods
Patients Ninety-sevenconsecutive patients diagnosed with unstable angina were treated with the combination of 10,000 units of standard porcine intestinalheparin,sodium USP deliveredorallyin125 -200 ml of water,combinedwith arginine (JoMar Laboratories, Campbell, CA, USA) administereda st wo 825 mg capsules by mouth twice daily. ThetotalL-argininedosewas 3.3 grams daily in all patients.The patients were instructed to immediatelygoto the emergency room for admission if their symptoms recurred or acceleratedd uring the subsequent 48 hours. Patients were referred for interventionaltreatmentifsymptoms failed to resolve within 72 hoursa nd if symptoms recurred at anyt ime within 12 months.A ll other current medicationsw erec ontinued, patients remained on aspirin, beta blockers,statin drugsand other treatments as were prescribedprior to the diagnosis. The resulting combined cardiac eventrates were compared to aseries of patient outcomesat12months postdiagnosisofunstableangina as reportedi nt he recentF RISCI IT rial ( 23) . This uncontrolled observationals tudyw as conductedi naprivate medicalp ractice. Since this wasnot acontrolled trial,noinformedconsentwas obtained.
Animal studies Drugs
Unfractionated bovine lung heparin (sodiumheparin 150 units/ mg, LotN oZ X320,U pjohn Ltd., Kalamazoo, MI, USA) was dissolvedinwater at aconcentration of 20 mg/ml. Sulodexide, a glycosaminoglycanm ixturec ontaining fast moving heparin 80% and dermatansulfate 20% (22) ,was obtainedfrom Keryx Biopharmaceuticals(NewYork, NY,USA). Sulodexide wasdissolved in watera taconcentration of 20 mg/ml for short-term studiesa nd 10 mg/mlf or long-terms tudies. Gelatin capsules containing arginine, similar to those usedinthe human studies, were opened,and contents were dissolvedinwater at aconcentration of 300 mg/mlfor 4-hour studies and 150 mg/mlfor the 28-daystudy.
Animals
One hundred eighty-twomaleWistarrats, weighing311 ±48g (± SD), were handled and housed according to the Principles of AnimalC are seto ut by the CanadianF ederation of Biological Societies. The animals were fasted overnightprior to treatment and were anaesthetized with barbitaland methoxyflurane for experimental procedures.
Drug administration
Forshorttermstudiesthe following treatment groups were used: saline,heparin, arginine, heparinplus arginine, sulodexide,and sulodexide plus arginine. Bovine heparin wasusedinthe animal studies in placeofthe porcine heparin used in the human study. The antithromboticresponseissimilarfor the twoheparins when giveno rallyi nt he ratv enous thrombosis model ( 26) . Heparin and sulodexide were administered at 7.5m g/kg basedo np reviouss tudiess howing a5 0% decrease in stable thrombus formations with unfractionated heparin in this animal model (2) . Arginine wasa dministereda t1 12.5 mg/kg to approximate the doseusedinthe human study.The dose of heparin or sulodexide wasassignedrandomly with6to8ratstreated per day. Astomach tube wasfilledwith 0.2 ml saline followedby0.10 -0.18 ml of heparin or sulodexide solution and 0.1 ml of arginine solution depending on ratw eight. Thus, when the stomach tube was placed in the stomach, the drugs were first introduced into the stomach and flushed in by saline to give at otal volume of approximately 0.4 ml. In the heparin onlygroup, heparin wasadministeredinavolume of 0.1 -0.2 ml followedby0.2 ml saline. Forlong-term studiessulodexide (2.9 mg/kg) plus arginine (42.9 mg/kg) were givend aily by stomacht ube for 28 days. Control rats treatedfor four hours were givensaline (0.3ml) by stomach tube.C ontrol rats treatedf or 28 days were kept in metabolic cages during that timeand were givenwater.
Thrombosistest
The thrombosistestwas performed in amodification of the procedure by Blake et al. (24) . Foranimals exposed to treatment for 4hours, athrombus wasinitiatedinthe right jugular vein by application of 10% formalin in 65% methanol to the exposed adventitial surface. Immediatelyfollowing, drugs were introduced into the stomach by stomachtube. At four hours after thrombus initiation, animals were again deeplya naesthetizeda nd first examinedf or anye xternal signs of bleeding.The jugular vein wasexamined for the presenceofaplug usingacotton pledget. The thrombus wasscored as +(stable thrombus) if the vesselwas blocked and remained blocked despite examination with acotton pledget. The thrombus wasscored as +/-(softorunstable thrombus) if the vesselappearedcompletelyblockedonfirst examination and theno peneda si tw as examined. Thet hrombus was scored as -( negative)i fb lood wass een to flow freelyi nt he vessel.
Forthe long-term(28-day) study,athrombus wasinitiatedin the jugularveinonthe final day, fourhours prior to killing the rats. The last (28 th )d ose wasa dministeredi mmediately after thrombus initiation. Thet hrombus wase valuateda sd escribed forshort-termstudies.
Collectionofblood andblood vessels
Immediately after examination of the jugularvein, alaparotomy wasp erformed and ab lood sample of approximately 10 ml (9 parts blood to 1part3.8% sodium citrate) wastaken fromthe abdominal aorta. Plasma wasprepared. As asourceofendothe-lium,the thoracic aorta wasremoved and placed in saline.Each animalwas examinedfor signs of internal hemorrhage, and the timewhen blood clotted in the body cavity wasrecorded.
Harvesting of endothelium
Endotheliumwas removed fromblood vessels according to the method of Hiebert and Jaques (25) . The vessels were slit open, pinned to dentalw ax lumenside up, and rinsed in Locke's solution. Cellulose acetatepaper wasapplied to the luminal surface and when lifted, endothelium wasremoved. Thelength and width of the imprint were measured to the nearestm illimeter. Harvested endothelialsurfacewas 2.28 ±0.74 (SD) and 0.57 ±0.25 cm 2 for aorta and vena cava,respectively.
Determinationofheparin andsulodexidewith endothelium
Celluloseacetatepaper wasremoved fromendothelium by dissolving in cold acetone followedbycentrifuging and discarding the supernatant.The precipitates were thend igestedw ith pronase (Sigma,S t. Louis, MO,U SA;1 0 µ go f4 0m g/ml in Tris buffer). Sampleswere thencentrifuged at 8,000xgfor 10 min, supernatant wascollectedand the precipitate washedtwice with 100 µ l2 6.8% NaCl that wasa dded to the supernatant. GAGs were precipitatedfrom the supernatant with five volumesofmethanol, and the precipitate wasdried. Agarosegel electrophoresis wasu sedt oi dentify and measure heparin in endothelial extractsbypreviouslypublished methods (1) .The driedpowders were dissolvedinwater and appliedtoagarosegel slides along witht he heparin or sulodexide used as references. Following electrophoresis, gels were fixedi n0 .1% hexadecyltrimethylammoniumb romide and air-dried. Slides were stained with 0.04% toluidine blue in 80% acetone,and background color was removedw ith 1% acetic acid. Heparina nd sulodexide were identifiedb yc omparing migration to reference material. Amounts contained in each sample were determinedbydensitometry.
Determinationofplasma anticoagulant activity
The activatedp artialt hromboplastin time( APTT) wasd eterminedusing akit from Biopool(Ve ntura,CA, USA). Anti-factor Xa and anti-factor IIa activity were measured using chromogenic assaykits, Accucolor TM Heparin ® (Sigma)and Spectrolyse ® Heparin,respectively.
Heparin concentrationi np lasma wasa lso measured using the Heptest (Accuclot TM Heptest ® ,Sigma)w heret he clotting timed eterminedw as converted to µg/ml by use of calibration curvesp repared at the same time with unfractionated bovine lung heparinorsulodexide.
Determinationofheparin andsulodexideinurine
Rats were placed in metabolic cages,a nd urine wasc ollected over the 4-hourperiod,or24-hour urineswere collected on day1, 7, 14, 21 and 28 in the 28-daystudy.Urine wasdialyzed against wateru sing 1,000 molecularw eightc ut off( MWCO) dialysis tubing (SpectrumChemicaland LaboratoryProducts, Gardena, CA,U SA). Ther esulting solution wasd ried and analyzed by agarose gelelectrophoresis as described above for endothelium.
Statisticalanalysis
Thrombosisd atai se xpressed as ap ercentage with 95% confidencei ntervals (2) . Test ford ifferences between proportions wasu sedt oc omparet he total thrombotici ncidence and incidenceofhard thrombus between groups. Rat weight and surface area of endothelium are expressed as mean±standard deviation (SD).Otherdataisexpressed as mean±SE.Aone-wayANOVA withT ukey's post hoc test wasusedtocomparethe differences betweengroups when plasma coagulation tests and heparino r sulodexide concentrations in urine were examined.
Results

Patients
Results from the cohortofpatients on dailymaintenance of heparin plus arginine, 12 monthsp ost diagnoses, ares hown in Table1 .T hese data showt hat the cardiace vent rates (death, myocardialinfarction, readmission and revascularization) were dramaticallyr educed compared to publishedd atau sing other treatment options. No othercomplications were observedinany patient. These resultsc omparefavorablyt ot hose of the recent FRISC II trial (23) at 12 months and showadramatic reduction of 49 -93% seenindeath, myocardialinfarction or secondary cardiovasculare vents without use of interventional treatment and areduction of 9-89% with interventional treatment.
Animal studies
On thebasis of these anecdotal results, showingeffectivenessof oralheparin and arginine on prothrombotic activity in humans, an animalmodel wasusedtoinvestigatepossible mechanisms. The ratjugular vein modelw as chosenasitisw ellestablished and has been previously used to study the antithromboticactivity of heparins givenbythe oralroute (2) .Sincemost of the previous studies in this venous thrombosis model have beenc onducted using bovine lung heparin, this sourcewas chosentostudy its effectsw ith arginine. Sulodexide,ag lycosaminoglycan mixture wasalso choseninthe repeated dose long-termstudy of 28 days, sinceitreportedlyhas loweranticoagulant activity and is suitable for long-termoral administration (22 botic activity,compounds recovered from the endothelium and urine,and anticoagulant activity following administration of heparin and sulodexide with and without arginine.
Thrombosisincidence
In the 4-hourstudies, rats treated with saline (control) showedan 80% incidenceo fh ard thrombi and an 88%i ncidence of total thrombotice vents (hard plus soft thrombi) (Fig. 1) . Wheno ral heparin (7.5m g/kg) wasa dministered, the incidenceo fh ard thrombi wass ignificantly reduced to 42% although the total thrombotic incidencew as minimallya ffected. When arginine (112.5 mg/kg)w as administered alone, the incidenceo fh ard thrombi wasreduced to 20%,significantly different from control butnot from heparin treatedrats, while totalthrombotic events were 50%, significantly less thanb oth control and heparin treatedr ats. When arginine plus heparin( 7.5 mg/kg) were administered orally,the incidenceofhard thrombi wasreduced to 5% and the totalthrombotic eventsw ere reduced to 30%,both significantly less thanc ontrol or heparin treatedr ats. When using sulodexide (7.5mg/kg) alone in the 4-hour study,the incidenceo fh ard thrombi was1 0% and the total thrombotici ncidencewas 30%, both significantly less thanobservedfor control or heparin treatedrats. When arginine plus sulodexide were administered,t he incidenceo fh ard thrombi was1 5%, and total thromboticincidence was45%, both significantly less thancontrol or heparin treatedratsbut not different than sulodexide treatment alone.
In the long-termstudy,control rats kept in metabolic cages for 28 days showeda75% incidenceofhard thrombi and a95% incidenceoftotal thromboticevents. Whenratswere treated with sulodexide (2.9mg/kg) plus arginine (42.9 mg/kg) for 28 days, incidenceo fh ard thrombi (10%) and totalt hrombotic events (30%) were similart or atst reated fourh ours with sulodexide alone or with sulodexide (7.5 mg/kg) plus arginine (112.5 mg/ kg). Rats treatedf or 28 days with sulodexide plus arginine showeds ignificantly less thrombotic eventst han 4-hour and 28-dayt reated control rats,a nd 4-hour heparin (7.5 mg/kg) treatedrats.
Recoveryfromendothelium
Extracts of endothelium applied to agarose gel electrophoresis showedthat heparin and sulodexide were detected in endothelial samples, as determinedb yb oth their migration distancea nd their staining characteristics (Fig. 2) . The concentrations of heparin and sulodexide found with endothelium areshown in Table  2 . As expected,e ndogenous glycosaminoglycans, migrating similar to sulodexide, were observedi nc ontrol endothelial samples while little if anyendogenous heparin wasdetected in these samples. Theendothelium from rats treatedwith oral heparinclearlyshowedthe presenceofheparin. Concentrations of heparin in both the aortic and vena cavalendothelium of rats were greatestw hen treatedw ith heparina lone,f ollowedb yt hose treatedw ith heparinp lus arginine and thenb yc ontrols. The meanconcentrations of heparin with endothelium of rats treated withheparin alonewere morethan an orderofmagnitude greater thanthat found with endothelium of control rats, while endothelium from rats treated with heparinp lus arginine were fourt o five timesgreater thancontrol endothelium.Ingeneral,more heparin and sulodexide were recovered from vena cavalendothelium than from aortic endothelium.
The recovery of sulodexide from the vena cavalendothelium wasgreatestfor rats treatedfor 28 days with sulodexide plus arginine. Sulodexide concentrations on aortic endothelium,for sulodexide plus arginine treatedgroups,was morethan twice that Figure1:Thrombosis incidence following administrationofheparin, sulodexide and/orarginineinarat model. Thrombosis was initiated by applicationofformalininmethanoltothe exposedright jugular vein. In the4-hourstudies, heparin (7.5 mg/kg) or sulodexide (7.5 mg/kg) and/or arginine (112.5 mg/kg) were administered,immediatelyafter thrombus initiation,bystomach tube.Incidence of thrombosis wasevaluatedfourhours later. In the28-daystudy,sulodexide (2.9 mg/ kg)and arginine (42.9 mg/kg) were administered dailybystomach tube. Athrombus was initiated four hoursprior to theend of theexperiment. Upwarddeflecting errorbarsshow95% confidence intervalsfor total thromboticevents, downwarddeflecting barsshow95% confidence intervals forhardthrombi. Significantly less than: 4-hour controlincidence of hardthrombi (A); 4-hour controltotalthromboticincidence (B); heparin alone incidence of hardthrombi (C); heparin alone totalthromboticincidence (D); 28-daycontrol incidence of hardthrombi (E); 28- of the control group. Endothelium from rats treatedwith arginine alones howedt wice thec oncentrations of sulodexide on aortic and vena cavalendothelium as that from control rats.
Anticoagulant activity APTT,Heptestand anti-factor Xa activity wasassessedtodetermine if sulodexide or heparinand/or arginine modified coagulation following orala dministration (Fig. 3) . Although only small changes were observedinAPTTinthe 28-daystudy of the sulodexide plus arginine group, the APTT in the 28-daygroup wassignificantly greater thanthe 4-hour treatedsulodexide plus arginine, the heparin plus arginine or the arginine alone treated groups. Interestingly, anti-factor Xa activity wass ignificantly greater in controls thaninthe groups treatedwith heparinplus arginine and arginine alone.I na ddition, the 28-days ulodexide plus arginine treatedgrouphad noticeably loweranti-factor Xa activity,and this activity wassignificantly lowerthan the heparin plus arginine treated, sulodexide treated and arginine alone treated groups. Little or no anticoagulant wasfound in plasma as determined by the anti-IIa assay.Noanti-IIaactivity wasdetected in plasma of the 4-hoursulodexide plus arginine, heparin plus arginine and the 28-daylong-term sulodexide plus arginine groups. Asmall amount of anti-IIa activity wasdeterminedinthe plasma of animals administered sulodexide alone and arginine alone (values equivalent to 1.43±0.97, and 4.36 ±5 .04 [SE] g/ml,r espectively).
Recoveryfromurine
When changes in the amount and concentration of urinary sulodexide with time were determinedb ye lectrophoresis with time for animals administered sulodexide plus arginine for28days, maximum increases in totalµgand µg/ml were seen at day7 (Fig.  4) . While the total amount of sulodexide remained elevated throughoutthe 28-dayperiod,its concentration in the urine declinedafter day7.With the exception of alarge spikeonday 1, Figure3:Changes in coagulation parametersfollowing administrationofsulodexide or heparin plus arginine to rats. In the 4-hour groups, heparin (7.5 mg/kg) or sulodexide (7.5 mg/kg) and/or arginine (112.5 mg/kg) were administered by stomachtube four hours priortoblood collection. In the 28-daystudy,sulodexide (2.9 mg/kg) and arginine (42.9 mg/kg) were administered dailybystomach tube,the lastdosegiven four hoursprior to blood collection. One-wayANOVA, Tu key's post hoc test. Results aresignificantlygreater than control(a); heparin (b); heparin plus arginine (c); sulodexide plus arginine (d); arginine (e); sulodexide plus arginine 28 days (f). P<0.05.
Figure4:Sulodexide-likecompounds in 24-hoururine samples at differentdaysfollowing long-term administration of sulodexide plusarginine. Sulodexide 2.9 mg/kg plus arginine 42.9 mg/kg were given by stomachtube dailyfor 28 days.Mean±SE areshown. One-wayANOVA.Tukey's post hoctest; significantlygreater than control (a); day1(b);day 21 (c); day28(d).P<0.05.
urinary anti-factor Xa activity levels closelyparalleledthe concentrations found by chemical determination. No anti-factor IIa activity wasfound in urine samples from control or experimental animals. Heparin and sulodexide were found only in small amountsinthe urine of rats treatedfor four hours with heparin or sulodexide, with heparin onlyt reated animals showingl evels significantlygreater thancontrol rats (data not shown).
Discussion
The results of the study of oral administrationofheparin plus arginine in unstable angina patients, suggest that this therapeutic approachc ompares favorably to both strategiesi np atients receiving subcutaneous LMWHinboth invasively and non-invasivelyt reated groups (23) .C ontrolled human studies, using a larger numbero fp atients, are required to establish the significance of heparinplus arginine on the variousendpoints,particularlyp atient death. Basedo nt hese anecdotalr esults, the same combination dosage of oral heparinplus arginine, as well as oral sulodexide plus arginine, and each agentalone were investigated in arat jugularveinthrombosis model. The resultsofthis animal study clearly demonstrate that orallyadministeredarginine has an antithrombotic effect in this rat thrombosis modelasdoes orally administered heparin.Inaddition, the administration of heparin plus arginine has additional antithrombotice ffectsw hen comparedtoheparin or arginine alone. Arginine didnot have the same synergistic effect when combined with sulodexide,a lthough sulodexide aloneh ad antithrombotic activity.These results suggest thatsulodexide and arginine mayact by asimilar mechanism whereas heparinh as additionala ntithrombotic effects.Sulodexide alone wasmore effective thanheparin alonein the short-termstudy.This maybedue to the presenceofdermatans ulfate or possible shorter chain length heparin (Mr (avg) 8,000) present in this glycosaminoglycanmixture (22) . These components of sulodexide maye xhibit afasterr ateo fo ral absorption and slowerrateofclearance thanobservedwith the unfractionated heparin (Mr (avg)~12,000) used here. This is consistent with our previous resultsinwhich lowmolecular weight heparins were effective at muchlower dosesthan unfractionated heparins (2) .
Adecision to do the long-term, 28-daystudy with onlysulodexide and arginine wasbased on the assumption thatsulodexide would cause less bleeding in long-termstudiesbecauseofits reduced anticoagulant activity compared to heparin. It is interesting to note that28-dayadministration of sulodexide and arginine waseffectiveinreducing thrombosis incidencebut not significantly different than 4-hour administration. However, the dose administered per dayoverthe 28-dayperiod,was less thaninthe 4-hour study.This suggests that long-termadministration results in an accumulation of the drug or its beneficial effects. Further studiesare warranted to examine this phenomenon,perhaps beginning with usingt he lowerd ose in as hort-terme xperiment (4 hours).
As in previous experiments (1) (2) (3) 26) , heparin wasrecovered from aortic and vena cavalendothelium following its oraladministration. In the present studies, arginine alone appearst oi ncrease the concentration of endogenous glycosaminoglycans on the vena cavalendothelium, consistent with the studies indicating that arginine upregulates the heparansulfate on the endothelialcellsurface. The highest recovery from endothelium wasobtained in the group treatedw ith heparina lone.M oreover,t he vena cavale ndothelium generallys howeds ubstantiallyh igher concentrations of heparinand glycosaminoglycanthan the aortic endothelium,agreeing with our previous work on orally administered low-molecular-weighth eparins (4, 27) . Heparin, however,was notrecovered from the endothelium of allanimals that showeda ntithrombotic activity.T his is probablyt he result of both the limited sensitivity of our assayand the sampling of only asmall amount of the totalendothelium, an averageof2.9 cm 2 of approximately 2m 2 of total endothelial surface. Since the migration of sulodexide under electrophoresis is similart oe ndogenous endothelial glycosaminoglycans, it wasdifficulttoestablish the presence of the exogenously administered sulodexide on the endothelium.
No evidenceofgastrointestinalirritation or bleeding wasobservedineitherhumans or rats during these investigations.There were only minor changes in the plasma anticoagulant activity followingoral administration of sulodexide or heparinascompared to controls. Noteworthy is the observedincrease in APTT in the group receiving long-terms ulodexide plus arginine. A similar small butsignificant increase in APTTw as seen in humans receiving repeated oral heparin at 20,000 units twice weeklyfor twotoeight months (28) . Our ownwork with dextran sulfates howedas imilari ncrease in APTT in humans treated 29-335 days with 1gram fourtimesper dayofdextran sulfate. This occurred despite dextran sulfateh aving one hundretht he anticoagulant activity of heparin (29) .Inthe present study,antifactor Xa activity wass ignificantly elevatedi nt he arginine alone,and the heparin plus arginine treatedgroups,leading one to speculatethat arginine mayhavesome effect on anti-factor Xa activity.Incontrast, anti-factor Xa activity waslow in the longterm 28-dayarginine plus sulodexide treated rats. Apossible explanation for this lowanti-factor Xa activity is that long-termadministration of sulodexide and arginine mayresultinchangesin production or consumption of coagulation factorstobalance the increasing anticoagulant effect of sulodexide or arginine.
Consistent withheparin binding to endothelium, little heparinorsulodexide wasrecovered from urine in the 4-hourstudy with onlythe group receiving heparinalone showingasignificant increase in urinary heparin concentration comparedtocontrols. This result might be explained by afasterrateofabsorption or excretion for heparin thanfor sulodexide, or for heparin or sulodexide in combination with arginine. Small amounts of heparinorsulodexide were found in the urine of allrats, as expected. In contrast to 4-hour administration, 28-daya dministration of sulodexide and arginine showedsignificant increases in glycosaminoglycans in the urine,beginningonday 1when anti-factor Xa activity wasmeasured,and on day7when measuredchemically. This supports the observations thatsulodexide is absorbed, and thatsome accumulation occurs throughout the 28-dayperiod,resulting in an increase in excreted material.
Since this studyshows that oralarginine plus heparinhas significantlyincreased antithromboticactivity compared to oral heparin alone, we speculatethat arginine enhancesthe absorption of heparin, and/or arginine enhancesh eparin'sa ntithrombotic activity.This is supported by the observation thatanti-factor Xa activity is significantly higher in heparin plus arginine treated rats thani nh eparin onlyt reated rats.( It should be notedt hat these changes in anti-factor Xa activity areminor although significant, Fig. 3) .Results from the analysis of the endothelium in this studyalso showlessheparin on the endothelium in the presenceofarginine thanwhen heparin is givenalone.
The clinicalresults reported suggest thatheparin is absorbed in humans followingoral administration and is distributedprimarily to endothelium. Thesestudiesare supportedbythe work of Engelbergwho showedincreases in APTT in ahuman study with oralh eparin (28)a nd by our owns tudiess howing an increase in anti-factor Xa activity and heparin in urine following a single dose of 7.5 mg/kg of heparin to humansubjects (30) .Arecent studyalso confirmssimilarendothelial deposition of heparinaswellasantithrombotic efficacywhen administered orally in arat modelofcarotid artery thrombosis (31) . In the current study,the observation thatarginine enhances the activity of orally administered heparin in both humans and animals, despite little change in plasma anticoagulant activity,i san ew finding and suggests that arginine and heparin have as ynergistic antithromboticeffect primarily on the endothelium.
The exact mechanism by whicharginine enhances the antithrombotic effect of oral heparinremains unknown, although enhanced absorption or enhancedendothelial antithromboticactivity,may contribute to these effects. Arginine onlyweaklybinds heparin (11) , so that it is unlikelythat arginine interacts with heparin in the body due to the presenceo fs alts and competing, higher-affinity heparin-binding proteins. We suggest insteadthat it is likelyt hat heparin and arginine exertt heir antithrombotic throughdifferent pathwaysbut in asynergistic fashion. Since arginine is as ubstrate for NO (5),t hese resultss uggest that NO mayplayarole in this phenomenon. Heparin increases NO activity through effects on eNOS (32) .NOenhances the production of endogenous endothelial anticoagulant heparans ulfate (14) .
Suchendogenous heparansulfateshavebeen shown to mediate flow-induced eNOS signaltransduction (33) . Thecellularuptake of heparansulfate proteoglycans has also been shown to be relatedtoNOcatabolism (20) . There has alsobeen arecent report implicating oral heparininenhanced NO production, whichaccelerates healing of gastric ulcers in animals (34) . Decreased excretion of heparini nt he presenceo fa rginine hasn ot beene xcludeda sa no perative mechanism for their synergistic antithrombotic effect.Moreover,itisinteresting that oralsulodexide also has antithromboticactivity thatisnot enhancedbyits co-administration with arginine.
Both endothelialheparan sulfateand NO effects areknown to be reducedi nt he atherothrombotic processesa sw ella si n aging in humans (35, 36) . Cholesterol plaque accumulation occursa ts iteso fr educed eNOS activity.R upture sites of culprit plaque lesions, responsible for unstable angina and myocardial infarction, showm arkedlyd epleted levels of endogenous proteoglycans compared to normala rterys egments (37) . The marked decrease in expected cardiovascularevents rates seenin suchpatients over a12-month period of using daily, continuous oral heparina nd arginine treatment suggests sustained passivation of plaque surfaces in these treated patients. Further studiesare required to assess the roles of NO production, endogenouse ndothelial heparans ulfate effects, coagulation factor complex assembly,thrombolytic processes, and other questions raised by the observations reported in the currentstudy.These results suggest the suitability of oral heparinorrelated glycosaminoglycans with arginine, with no demonstrated adversereactions and absence of systemic anticoagulation effects, forl ong-term antithrombotic prophylaxis and treatment in larger humana nd animal trials.
